Replies to post #12344 on Titan Pharmaceuticals Inc (TTNP)

[Doctor Detroit]

Yep. Agree with Serenity that Alkermes can't afford for another company to come to market with what is essentially a Vivitrol implant.

Also interesting that this happened this Summer...and shortly thereafter Titan announced a feasibility study for a kappa opioid agonist like CR845. Since CR845 has issues with being orally bioavailable, it would make sense for Cara to investigate an implant. They have a lot of money invested in this drug.

https://www.forbes.com/sites/kenkam/2017/07/06/cara-therapeutics-new-pain-drug-still-has-value-after-failed-clinical-trial/#505ff3631272

[Doctor Detroit]

This language from the most recent press release is, IMHO, more exciting than the Opiant deal.

"Additional ProNeura feasibility evaluations are ongoing in the area of chronic pain treatment with a peripherally acting Kappa opioid receptor agonist, and in the treatment of type 2 diabetes with currently approved peptides."

Remember, Titan has said it will not initiate any new product develop programs unless it has a partner/government funding source from Day 1 (apparently they will keep parkinsons and T3 for themselves until a later date).

I'm 99% sure the kapa opioid receptor agonist partner would be Cara Therapeutics, who has the cash to fund development.

The most likely partner for type 2 diabetes with currently approved peptides would be Novo Nordisk, who held the recently expired patent on Victoza and will be anxious to retain market share.